DPY19L1 Activators
DPY19L1, as a C-mannosyltransferase, holds a unique position in the cellular glycosylation machinery. Its involvement in protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan situates it in a specialized niche within the diverse landscape of protein glycosylation. Activators of DPY19L1 are of interest due to their influence this specific type of glycosylation.
UDP-Glucose stands out as it ensures substrate availability for glycosyltransferases, maintaining a conducive environment for DPY19L1. Agents like Tunicamycin, which inhibits N-linked glycosylation, can shift cellular priorities, making C-linked glycosylation more prominent. PUGNAc, by elevating O-GlcNAcylation levels, indirectly alters the balance of glycosylation, possibly benefiting DPY19L1 activity. Compounds like Deoxymannojirimycin and Swainsonine breakdown of glycosylated molecules, ensuring a rich substrate environment. Mannose, as a direct substrate, also deserves attention. Its abundance ensures DPY19L1 has the necessary raw materials to carry out its function. Compounds like Miglustat and Celgosivir that alter glycolipid levels or early N-glycan processing steps respectively can change the glycosylation landscape, driving increased DPY19L1 activity. Kifunensine, by inhibiting mannosidase I, can elevate high mannose N-glycan levels, thus influencing the glycosylation balance in favor of processes involving DPY19L1. Finally, Azasugars, depending on their specific targets, provide a versatile toolkit to modulate glycosylation, impacting DPY19L1's role.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Uridine 5′-diphosphoglucose disodium salt from Saccharomyces cerevisiae | 28053-08-9 | sc-222402 sc-222402A | 10 mg 25 mg | $27.00 $34.00 | ||
Donor substrate for glycosyltransferases. Its presence can influence glycosylation pathways. By ensuring an ample supply of UDP-Glucose, it can indirectly influence DPY19L1's mannosyltransferase activity by maintaining substrate availability for associated enzymes. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Known to inhibit N-linked glycosylation. By specifically inhibiting N-glycosylation, it might shift the cellular machinery to prioritize other glycosylation pathways, including C-linked glycosylation where DPY19L1 functions. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $224.00 $380.00 | 3 | |
Inhibitor of O-GlcNAcase. By inhibiting O-GlcNAcase, PUGNAc increases protein O-GlcNAcylation levels. This can indirectly influence C-mannosylation pathways by modifying the cellular glycosylation landscape and potentially increasing DPY19L1 activity. | ||||||
N-(n-Butyl)deoxygalactonojirimycin | 141206-42-0 | sc-221974 | 5 mg | $350.00 | 4 | |
Inhibits alpha-galactosidase A. The accumulation of glycosphingolipids might redirect cellular glycosylation pathways, potentially creating an environment where DPY19L1 activity becomes more prevalent. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Alpha-mannosidase inhibitor. By inhibiting breakdown, it increases the pool of certain glycosylated compounds, potentially influencing the balance of glycosylation processes and indirectly impacting DPY19L1 activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Inhibits mannosidase II. Accumulation of high mannose N-glycans can influence the cellular glycosylation processes, potentially providing an indirect impact on DPY19L1 activity through pathway modulation. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Beta-glucosidase inhibitor. By altering glucosylated compound levels, the glycosylation landscape within the cell is indirectly impacted. This might influence other glycosylation pathways, including the ones where DPY19L1 is involved. | ||||||
D-Mannose | 3458-28-4 | sc-211180 sc-211180A | 100 g 250 g | $103.00 $161.00 | 1 | |
Mannose serves as a key substrate for various mannosyltransferases. Ensuring high availability can potentially increase DPY19L1's mannosyltransferase activity by providing an abundant supply of substrate for C-mannosylation processes. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Inhibitor of glucosidase I. By influencing early steps in N-glycan processing, it can indirectly affect the broader glycosylation landscape in cells, which might in turn modulate DPY19L1's activity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Inhibits mannosidase I. By increasing levels of high mannose N-glycans, it can influence cellular glycosylation balance, potentially redirecting activity toward C-mannosylation pathways where DPY19L1 operates. | ||||||